+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Continuous Glucose Monitoring Market, By Component, By Demographics, By End User, Estimation & Forecast, 2017 - 2030

  • ID: 5511306
  • Report
  • October 2021
  • Region: Asia Pacific
  • 182 Pages
  • Astute Analytica
UP TO OFF until May 26th 2022

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Abbott Laboratories
  • DexCom, Inc.
  • Echo Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlySens Incorporated
The Asia Pacific Continuous Glucose Monitoring (CGM) market held a market value of USD 1,081.6 Million in 2021 and is projected to reach USD 2,967.2 Million by the year 2030. The market is anticipated to grow at a CAGR of 12.22% from 2022 to 2030.





Continuous Glucose Monitors (CGM) are devices used for monitoring blood glucose continuously. The market is expected to be driven by the increased awareness among people towards monitoring and preventive health. Furthermore, surge in diabetic population are also estimated to fuel the market growth.

Despite the driving factors, inaccurate and expensive systems are also expected to hinder the market growth. Also, inadequate reimbursement facilities are anticipated to act as a barrier for the market growth.

Growth Influencers:


Surge in diabetic population

Increasing prevalence of diabetes is also leading to surge in the diabetic population, which is boosting the market growth. According to the International Diabetes Federation (IDF), as of November 2019, around 88 million adults in South East Asia region were suffering from diabetes. This number was estimated to reach about 153 million by 2045. Therefore, surge in the diabetic population is expected to boost the demand for continuous glucose monitors, hence fuelling the market growth.

Segments Overview:


The Asia Pacific Continuous Glucose Monitoring (CGM) market is segmented into component, demographics, and end user.

By Component

  • Sensors
  • Transmitters and Receivers
  • Integrated Insulin Pumps
  • Others

The sensors segment is estimated to hold the largest market share of about 44% owing to the increasing technological advancements. The transmitters and receivers segment is expected to account for the second largest market share. They are the most durable component of the CGM device, which contributes to its market growth.

By Demographics

  • Child Population (< 14 Years)
  • Adult Population (>14 Years)

The adult population segment is anticipated to hold the largest market share and is also expected to grow at the fastest growth rate of 12.49% over the projected period owing to high incidence rate of diabetes in adult population as compared to the child population.

By End User

  • Diagnostics/Clinics
  • ICUs
  • Home Healthcare

The ICUs segment is expected to account for approximately 45% of the home healthcare segment’s market size in 2021 and this share is expected to reach 41% in 2030. The home healthcare segment is estimated to witness significant growth owing to growing adoption of CGM devices in homes.

Country Overview


By country, the Asia Pacific Continuous Glucose Monitoring (CGM) market is divided into China, India, Japan, South Korea, Australia & New Zealand, Indonesia, ASEAN, and the Rest of Asia Pacific. ASEAN is further classified into Malaysia, Thailand, Philippines, Vietnam, Singapore, and Indonesia.

China segment is estimated to hold the largest market share of around 36.2% owing to the increasing prevalence of diabetes in China. According to the International Diabetes Federation (IDF), as of November 2019, there are around 114 million cases of diabetes in China.

On the other hand, India is expected to witness the fastest growth rate of 13.35% during the forecast period owing to the rising adoption technologically advanced products in the country for management of diabetes and other such chronic diseases.

Competitive Landscape


Major players in the Asia Pacific Continuous Glucose Monitoring (CGM) market include Abbott Laboratories, DexCom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, and Other prominent players. The cumulative market share of the nine major players is over 78%.

These market players are engaged in mergers & acquisitions, collaborations, and new product launches, among other initiatives, to strengthen their market presence. For instance, in August 2021, Abbott received the U.S. FDA approval for the Freestyle Libre 2 iOS application, which is compatible with iPhones. This provided a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system.

The Asia Pacific Continuous Glucose Monitoring (CGM) market report provides insights on the below pointers:

  • Market Penetration: Provides comprehensive information on the market offered by the prominent players
  • Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  • Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
  • Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Asia Pacific Continuous Glucose Monitoring (CGM) market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
  • Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The Asia Pacific Continuous Glucose Monitoring (CGM) market report answers questions such as:

  • What is the market size and forecast of the Asia Pacific Continuous Glucose Monitoring (CGM) Market?
  • What are the inhibiting factors and impact of COVID-19 on the Asia Pacific Continuous Glucose Monitoring (CGM) Market during the assessment period?
  • Which are the products/segments/applications/areas to invest in over the assessment period in the Asia Pacific Continuous Glucose Monitoring (CGM) Market?
  • What is the competitive strategic window for opportunities in the Asia Pacific Continuous Glucose Monitoring (CGM) Market?
  • What are the technology trends and regulatory frameworks in the Asia Pacific Continuous Glucose Monitoring (CGM) Market?
  • What is the market share of the leading players in the Asia Pacific Continuous Glucose Monitoring (CGM) Market?
  • What modes and strategic moves are considered favorable for entering the Asia Pacific Continuous Glucose Monitoring (CGM) Market?
Frequently Asked Questions about the Asian Pacific Continuous Glucose Monitoring Market

What is the estimated value of the Asian Pacific Continuous Glucose Monitoring Market?

The Asian Pacific Continuous Glucose Monitoring Market was estimated to be valued at $1081.6 Million in 2021.

What is the growth rate of the Asian Pacific Continuous Glucose Monitoring Market?

The growth rate of the Asian Pacific Continuous Glucose Monitoring Market is 11.9%, with an estimated value of $2967.2 Million by 2030.

What is the forecasted size of the Asian Pacific Continuous Glucose Monitoring Market?

The Asian Pacific Continuous Glucose Monitoring Market is estimated to be worth $2967.2 Million by 2030.

Who are the key companies in the Asian Pacific Continuous Glucose Monitoring Market?

Key companies in the Asian Pacific Continuous Glucose Monitoring Market include Abbott Laboratories, DexCom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc. and La Roche Ltd..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • A. Menarini Diagnostics
  • Abbott Laboratories
  • DexCom, Inc.
  • Echo Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlySens Incorporated
Chapter 1. Research Framework
1.1 Research Objective
1.2 Product Overview
1.3 Market Segmentation

Chapter 2. Research Methodology
2.1 Qualitative Research
2.1.1 Primary & Secondary Sources
2.2 Quantitative Research
2.2.1 Primary & Secondary Sources
2.3 Breakdown of Primary Research Respondents, By Region
2.4 Assumption for the Study
2.5 Market Size Estimation
2.6. Data Triangulation

Chapter 3. Executive Summary: Asia Pacific Continuous Glucose Monitoring (CGM) Market

Chapter 4. Asia Pacific Continuous Glucose Monitoring (CGM) Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Developer
4.1.2. Technology Integrator
4.1.3. Service Provider
4.1.4. End User
4.2. Industry Outlook
4.2.1. Prevalence of diabetes in Asia Pacific
4.2.2. Sales of Continuous Glucose Monitoring Devices in Asia Pacific
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Restraints
4.5.3. Challenges
4.5.4. Key Trends
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.2. Price Trend Analysis, By Product
4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2020
4.8.3. Competitor Mapping

Chapter 5. Continuous Glucose Monitoring (CGM) Market Analysis, By Application
5.1. Key Insights
5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
5.2.1. Sensors
5.2.2. Transmitters & Receivers
5.2.3. Integrated Insulin Pumps
5.2.4. Others

Chapter 6. Continuous Glucose Monitoring (CGM) Market Analysis, By Demographics
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
6.2.1. Child Population (< 14 years)
6.2.2. Adult Population (>14 years)

Chapter 7. Continuous Glucose Monitoring (CGM) Market Analysis, By End user
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
7.2.1. Diagnostics/Clinics
7.2.2. ICUs
7.2.3. Home Healthcare

Chapter 8. Continuous Glucose Monitoring (CGM) Market Analysis, By Region
8.1. Key Insights
8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Australia & New Zealand
8.2.6. Indonesia
8.2.7. ASEAN
8.2.7.1. Malaysia
8.2.7.2. Thailand
8.2.7.3. Philippines
8.2.7.4. Vietnam
8.2.7.5. Singapore
8.2.8. Rest of Asia Pacific

Chapter 9. China Continuous Glucose Monitoring (CGM) Market Analysis
9.1. Key Insights
9.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
9.2.1. By Component
9.2.2. By Demographics
9.2.3. By End User

Chapter 10. India Continuous Glucose Monitoring (CGM) Market Analysis
10.1. Key Insights
10.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
10.2.1. By Component
10.2.2. By Demographics
10.2.3. By End User

Chapter 11. Japan Continuous Glucose Monitoring (CGM) Market Analysis
11.1. Key Insights
11.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
11.2.1. By Component
11.2.2. By Demographics
11.2.3. By End User

Chapter 12. South Korea Continuous Glucose Monitoring (CGM) Market Analysis
12.1. Key Insights
12.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
12.2.1. By Component
12.2.2. By Demographics
12.2.3. By End User

Chapter 13. Australia & New Zealand Continuous Glucose Monitoring (CGM) Market Analysis
13.1. Key Insights
13.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
13.2.1. By Component
13.2.2. By Demographics
13.2.3. By End User

Chapter 14. ASEAN Continuous Glucose Monitoring (CGM) Market Analysis
14.1. Key Insights
14.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
14.2.1. By Component
14.2.2. By Demographics
14.2.3. By End User
14.2.4. By Country

Chapter 15. Indonesia Continuous Glucose Monitoring (CGM) Market Analysis
15.1. Key Insights
15.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
15.2.1. By Component
15.2.2. By Demographics
15.2.3. By End User

Chapter 16. Rest of Asia Pacific Continuous Glucose Monitoring (CGM) Market Analysis
16.1. Key Insights
16.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)
16.2.1. By Component
16.2.2. By Demographics
16.2.3. By End User

Chapter 17. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
17.1. Abbott Laboratories
17.2. DexCom, Inc.
17.3. A. Menarini Diagnostics
17.4. Echo Therapeutics, Inc.
17.5. GlySens Incorporated
17.6. Johnson & Johnson
17.7. Medtronic plc
17.8. Senseonics Holdings, Inc.
17.9. F. Hoffmann-La Roche Ltd.
17.10. Other Prominent Players
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • DexCom, Inc.
  • A. Menarini Diagnostics
  • Echo Therapeutics, Inc.
  • GlySens Incorporated
  • Johnson & Johnson
  • Medtronic plc
  • Senseonics Holdings, Inc.
  • F. Hoffmann-La Roche Ltd.
Note: Product cover images may vary from those shown